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Abstract
A large mutation screening of 504 patients with muscular dystrophy or myopathy has been performed by next generation sequencing (NGS).
Among this cohort of patients, we report a case with a severe form of muscular dystrophy with a proximal weakness in the limb-girdle muscles.
Her biopsy revealed typical dystrophic features and immunohistochemistry for α- and γ-sarcoglycans showed an absent reaction, addressing the
clinical diagnosis toward a sarcoglycanopathy. Considering that no causative point mutation was detected in any of the four sarcoglycan genes, we
re-evaluated the NGS data by careful quantitative analysis of the specific reads mapping on the four sarcoglycan genes. A complete absence of
reads from the sixth exon of the β-sarcoglycan gene was found. Subsequent array comparative genomic hybridization (CGH) analysis confirmed
the result with the identification of a novel 3.3 kb intragenic deletion in the SGCB gene. This case illustrates the importance of a multidisciplinary
approach involving clinicians and molecular geneticists and the need for a careful re-evaluation of NGS data.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
Limb girdle muscular dystrophies (LGMDs) are a large
group of heterogeneous autosomal disorders that are
somewhat similar, but milder than X-linked Duchenne
muscular dystrophy (DMD). As in DMD, a progressive muscle
wasting produces an initial weakness of the pelvic and/or
shoulder girdle muscles [1].
The sarcoglycanopathies are severe forms of LGMD
closely related to the dystrophinopathies. Pathogenic variants in
any of the sarcoglycan (SGC) genes produce an imperfect
dystrophin- associated SGC complex that fails to localize at the
muscle membrane. A stable muscle SGC complex must be
heterotetrameric with a 1:1:1:1 ratio between α-, β-, γ- and
δ-sarcoglycan with some exceptions in the cardiac and smooth
muscles, where ε-sarcoglycan may replace α- sarcoglycan
[2–4]. Sarcoglycanopathies usually have a childhood onset. The
quadriceps and posterior thigh muscles are affected together
with the shoulders. The progression tends to be more rapid than
that of other LGMDs, with a loss of ambulation usually at
12–16 years. Patients with a late onset generally have a slower
and more benign course. Cardiomyopathy is reported in about
30% of cases, but it is less common than in LGMD2D. A
progressive weakness leads to restrictive lung disease and
hypoventilation so that ventilator assistance is often necessary
[5,6]. Cognitive impairment has never been described in
patients with sarcoglycanopathy.
In contrast with the Duchenne and Becker muscular
dystrophies that are commonly caused by large intragenic
deletions/duplications in DMD, mutations in SGC genes are
typically small defects, such as single nucleotide substitutions
or short deletions/insertions. The large size of the DMD gene
(2200 kb) may partially explain the difference in mutation
types. Similarly, a greater number of intragenic deletions/
duplications should also be expected in the SGCG (144 kb) and
the SGCD (433 kb) compared with the SGCA (10 kb) or the
SGCB (15 kb) genes.
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SGCG deletions have been identified by multiplex
ligation-dependent probe amplification (MLPA) analysis or
targeted array CGH [7–9], and complete exonic deletions of
the SGCA gene and partial duplications of different exons
of the SGCB gene have also been described [6,10,11].
Furthermore, in the context of contiguous gene deletion
syndrome, a homozygous 400 kb deletion, also comprising the
SGCB gene, has been mapped by FISH and Southern blot in a
large consanguineous East-Anatolian family with an LGMD
phenotype [12].
By using MotorPlex, an NGS-based platform for
simultaneously testing 93 genes related to primary skeletal
muscle diseases [13], we recently performed an extensive
mutation screening in a large cohort of 504 patients affected by
an LGMD or a myopathy.
In this study, we describe a novel intragenic deletion at the
SGCB locus, identified by an NGS approach and mapped by an
array CGH, associated with a severe LGMD phenotype.
2. Case presentation
A female child was born from healthy parents and her family
history was negative.
She started presenting a proximal weakness in the limb
girdle muscles in early childhood. A neurological examination
at the age of 9 years showed a waddling gait, positive Gowers’
sign, muscle hypertrophy of the calves and the quadriceps
femoris, macroglossia, a severe muscle weakness in the
proximal muscles of all four limbs, absent deep tendon reflexes
and a high arched palate. Her CK levels ranged from 6549 to
7924 U/L (n.v. 0–190 U/L). EMG showed diffuse myopathic
changes.
A quadriceps muscle biopsy showed severe dystrophic
changes, consisting of increased fiber size variability, increased
central nuclei, opaque fibers, degenerating and regenerating
fibers, and marked endomysial fibrosis. Immunohistochemical
investigations for α- and γ-sarcoglycan showed an absent
reaction.
As a first level genetic test, the patient’s genomic DNA was
analyzed by using Motorplex, a customized NGS panel for the
targeted enrichment of selected genes causing primary skeletal
muscle diseases [13]. All the exons and ten intronic flanking
bases of the 93 genes included in the MotorPlex design were
specifically sequenced on a HiSeq1000 instrument (Illumina,
USA).
On average, targeted resequencing generated 4.1 Mb of
sequence data as 100-bp paired-end reads. The sequence data
were analyzed using an in-house pipeline designed to automate
the analysis workflow [14].About 92.1% of the targeted regions
were read more than 100 times, ensuring the detection of
genetic variants with a high sensitivity and specificity.
None of rare variants (frequency <0.01) identified in this
patient after data filtering appeared to be pathogenetic or in
accord with the observed clinical phenotype and the manner of
inheritance.
Meanwhile, a Western blot analysis with different primary
antibodies showed the absence of α-sarcoglycan protein (Fig. 1)
and a normal expression of the dystrophin, dysferlin, and
calpain-3 proteins (data not shown).
The strong clinical suspicion of sarcoglycanopathy,
confirmed by the immunohistochemical and Western blot
results, led us to re-evaluate the NGS data, focusing our
attention on the SGC genes. By checking the coverage obtained
by the NGS data for these genes, we discovered the absence of
any read on the last exon of the SGCB gene, unlike all of the
other samples analyzed (Fig. 2a). A homozygous deletion in
the last exon of SGCB was suspected. The amplification of all
the exons showed no PCR products for exon 6 in the patient
compared to a control.
To confirm the deletion, we performed array CGH analysis
using Motor Chip, an oligonucleotide-based 8X60Kmicroarray
(Agilent Technologies, USA) with exon-specific gene coverage
in 245 genes involved in neuromuscular disorders, as well as
180 candidate disease genes [7]. Motor Chip was able to further
define this novel homozygous deletion that included the last 12
codons of exon 6 and the 3′UTR of the SGCB gene, spanning
about 3.3 kb at 4q12 (Fig. 2b).
Fig. 1. A western blot analysis with different primary antibodies showed the
absence of α-sarcoglycan protein.
Fig. 2. Graphic view of NGS and array CGH results. (a) IGV graphic view of
the SGCB gene coverage in a control (upper panel) and in the proband sample
(lower panel); (b) Motor Chip profile of the last 12 codons of exon 6 and the
3′UTR SCGB deletion.
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3. Discussion
The development of NGS technologies has improved the
genetic understanding of various diseases, especially disorders
characterized by a genetic and phenotypic heterogeneity.
For LGMDs, where the list of genes to be screened is too
large for the gene-by-gene approach, a targeted NGS approach,
with panels including all the genes so far associated with these
disorders, represents a straightforward strategy [13].
For the patient described here, the NGS analysis was initially
negative as no pathogenic variants were identified. However, the
strong clinical suspicion of a sarcoglycanopathy directed us to
a re-evaluation of the NGS data, by careful quantitative analysis
of the specific reads mapping on the four sarcoglycan genes.
The absence of reads in the sixth exon of the SGCB gene was
observed, suggesting a homozygous deletion, subsequently
confirmed using Motor Chip for a better definition of this copy
number variation (CNV).
CNVs are a rare occurrence in the sarcoglycanopathies
[10–12]. However, the number of CNVs in the SGC genes
could be underestimated because of the limitations of standard
technologies.
To date, the bioinformatics tools for the detection of CNVs
from NGS data do not provide a sufficient specificity and
sensitivity [15]. Any NGS tool is able to investigate single
nucleotide variants but it can only suggest the presence of
gene deletions/duplications, as described here. An array CGH
analysis should anyway be carried out either to confirm or
better characterize putative CNVs suggested by the NGS
analysis or to reveal CNVs when no causative mutations have
been identified.
Although conventional molecular methods are still
important for clinical application, this report highlights the
increased role of NGS in routine clinical diagnostics and the
need for a careful interpretation of the results by a molecular
geneticist. NGS tools are used as a first tier test for most
diagnostic centers, despite the fact that they should be a last
resort for LGMDs according to the American Academy of
Neurology Guidelines [16].
The employment and the cost-effectiveness of the NGS
analysis in the LGMD diagnostic workflow are still debatable
[17]. A large study comparing patients who had undergone a
biopsy first followed by NGS testing versus patients tested with
NGS as the first step should be performed to definitively
demonstrate the cost- and time-effectiveness of the NGS
approach.
Regardless of the effective order of the diagnostic workflow,
a multidisciplinary approach involving clinicians and
molecular geneticists is crucial for the correct interpretation of
data generated by these high throughput technologies, as clearly
demonstrated here.
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